| 1. |
|
|
| 2. |
- Mattsson, Niklas, 1979, et al.
(författare)
-
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
- 2011
-
Ingår i: Alzheimer's & dementia : the journal of the Alzheimer's Association. - : Wiley. - 1552-5279. ; 7:4
-
Tidskriftsartikel (refereegranskat)abstract
- The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.
|
|
| 3. |
- Shanks, Hayley R. C., et al.
(författare)
-
p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial
- 2024
-
Ingår i: NATURE MEDICINE. - 1078-8956 .- 1546-170X. ; 30:5
-
Tidskriftsartikel (refereegranskat)abstract
- p75 neurotrophin receptor (p75NTR) signaling pathways substantially overlap with degenerative networks active in Alzheimer disease (AD). Modulation of p75NTR with the first-in-class small molecule LM11A-31 mitigates amyloid-induced and pathological tau-induced synaptic loss in preclinical models. Here we conducted a 26-week randomized, placebo-controlled, double-blinded phase 2a safety and exploratory endpoint trial of LM11A-31 in 242 participants with mild to moderate AD with three arms: placebo, 200 mg LM11A-31 and 400 mg LM11A-31, administered twice daily by oral capsules. This trial met its primary endpoint of safety and tolerability. Within the prespecified secondary and exploratory outcome domains (structural magnetic resonance imaging, fluorodeoxyglucose positron-emission tomography and cerebrospinal fluid biomarkers), significant drug-placebo differences were found, consistent with the hypothesis that LM11A-31 slows progression of pathophysiological features of AD; no significant effect of active treatment was observed on cognitive tests. Together, these results suggest that targeting p75NTR with LM11A-31 warrants further investigation in larger-scale clinical trials of longer duration. EU Clinical Trials registration: 2015-005263-16; ClinicalTrials.gov registration: NCT03069014. A phase 2a trial of LM11A-31 in mild to moderate Alzheimer disease suggests that p75NTR modulation is safe and attenuates measures of degeneration.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Bulanova, Daria, et al.
(författare)
-
Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins
- 2017
-
Ingår i: Viruses. - : MDPI AG. - 1999-4915. ; 9:10
-
Tidskriftsartikel (refereegranskat)abstract
- Viral diseases remain serious threats to public health because of the shortage of effective means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced the premature death of cells infected with different RNA or DNA viruses, whereas, at the same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest that Bcl-2i sensitizes cells containing foreign RNA or DNA to apoptosis. A comparison of the toxicity, antiviral activity, and side effects of six Bcl-2i allowed us to select A-1155463 as an antiviral lead candidate. Thus, our results pave the way for the further development of Bcl-2i for the prevention and treatment of viral diseases.
|
|
| 7. |
- Froitzheim, Jan, 1981, et al.
(författare)
-
Nano coated interconnects for SOFC (NaCoSOFC)
- 2013
-
Ingår i: ECS Transactions. - : The Electrochemical Society. - 1938-5862 .- 1938-6737. ; 57:1, s. 2187-2193
-
Konferensbidrag (refereegranskat)abstract
- The NaCoSOFC project is focused on the development of nano coatings for SOFC interconnects. The project is sponsored by the Nordic Top Level Research Initiative and has four project partners: Sandvik Materials Technology which is producing coated interconnects, Chalmers University of Technology and the University of Oslo that characterize samples with respect to e.g. corrosion, Cr evaporation and ASR as well as Topsoe Fuel Cell that is testing the developed interconnects in its stacks. The developed coatings are based on a combination of Co with RE elements and exhibit high corrosion resistance, 10 fold decrease in Cr evaporation and ASR values that are approximately 50% of the uncoated material.
|
|
| 8. |
- Grolig, Jan Gustav, 1986, et al.
(författare)
-
Copper based conversion coatings on ferritic stainless strip steel as solid oxide fuel cell interconnects: Oxidation performance and chromium evaporation
- 2013
-
Ingår i: ECS Transactions. - : The Electrochemical Society. - 1938-5862 .- 1938-6737. ; 57:1, s. 2339-2347
-
Konferensbidrag (refereegranskat)abstract
- Ferritic stainless steels such as Crofer 22 H or Sanergy HT have been proven to be effective interconnect materials when additionally coated. These coatings, mainly based on cobalt spinels, successfully prevent chromium evaporation and are stable for long exposure times. A new approach is using copper based spinel coatings which are promising concerning price, conductivity and stability. This investigation is dedicated to a selection of copper spinel conversion coatings, their stability and ability to prevent chromium evaporation. Chromium release was monitored in humidified air (at 850 °C) using the denuder technique. The coatings were post analysed utilizing electron microscopy.
|
|
| 9. |
|
|
| 10. |
|
|
